B.O.S.S. Retirement Advisors LLC Makes New $1.69 Million Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

B.O.S.S. Retirement Advisors LLC acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 4,078 shares of the company’s stock, valued at approximately $1,686,000.

Several other large investors have also recently added to or reduced their stakes in the business. Public Sector Pension Investment Board boosted its holdings in shares of IDEXX Laboratories by 67.6% in the second quarter. Public Sector Pension Investment Board now owns 3,078 shares of the company’s stock valued at $1,500,000 after acquiring an additional 1,241 shares in the last quarter. Marshall Wace LLP boosted its position in IDEXX Laboratories by 2.5% during the 2nd quarter. Marshall Wace LLP now owns 20,500 shares of the company’s stock worth $9,988,000 after acquiring an additional 500 shares during the period. Deerfield Management Company L.P. Series C purchased a new position in IDEXX Laboratories during the 2nd quarter valued at about $933,000. Daymark Wealth Partners LLC increased its holdings in shares of IDEXX Laboratories by 37.1% in the 2nd quarter. Daymark Wealth Partners LLC now owns 621 shares of the company’s stock valued at $303,000 after purchasing an additional 168 shares during the period. Finally, MBB Public Markets I LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter worth approximately $2,931,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $435.33 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The stock has a market cap of $35.65 billion, a P/E ratio of 41.98, a PEG ratio of 3.63 and a beta of 1.36. The company’s 50-day simple moving average is $423.74 and its 200 day simple moving average is $456.35. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. During the same period last year, the business earned $2.53 earnings per share. The business’s revenue was up 6.6% on a year-over-year basis. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 2.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IDXX. JPMorgan Chase & Co. lowered their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Barclays dropped their target price on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Finally, Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $523.86.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.